Pain Management · OTCSafety Signalcommercialnear-term

Omega Pharma recalls Napralief 250mg Tablets due to PIL deficiencies

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/29/2026, 12:33:25 PM

Assessment confidence: 86% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The recall of Napralief 250mg due to deficiencies in the Patient Information Leaflet poses a risk to Omega Pharma's market position and consumer trust. Competitors may capitalize on this situation, necessitating a proactive response from portfolio teams to mitigate potential impacts. Regulatory context from MHRA (Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28) supports the near-term read. Assessment grounded in 2 ranked evidence items (2 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this recall on market share and consider strategies to mitigate consumer concerns. The strongest clinical anchor is Evaluation of the Japet.W+ Medical Device for Low Back Pain Management (ClinicalTrials.gov), sub-indication match (pain). The recall could lead to a decline in sales and market share for Napralief, allowing competitors to gain traction in the OTC pain management sector.

Competitive Pressure

The most relevant competitive pressure comes from This recall may impact consumer trust and sales of Napralief, potentially benefiting competitors in the OTC pain management market..

Regulatory Outlook

Regulatory risk is concentrated around The recall may prompt scrutiny from regulatory bodies regarding compliance and labeling standards, which could affect future approvals or product launches..

Key Risks

Elevated medium regulatory exposure for Omega Pharma Ltd could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

The recall could lead to a decline in sales and market share for Napralief, allowing competitors to gain traction in the OTC pain management sector.
Portfolio teams should assess the impact of this recall on market share and consider strategies to mitigate consumer concerns.

What Would Change This Assessment

This becomes more urgent if Monitor for updates on the recall process and any potential regulatory actions or consumer reactions.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28
MHRAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Report on the State of Pharmaceutical Quality
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Human Experimental Models of Pain (HEMP)
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

[Ad hoc announcement pursuant to Art.
Rochelow relevance
Sponsor/company relevance (Roche)
FDA document
View source
Mölnlycke Health Care Recalls Hibiwash Due to Microbial Contamination
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
Bayer Plc Issues Class 3 Recall for Various Products Due to Impurity
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities
GE HealthCare Issues Correction for Infant Resuscitation Systems Due to Oxygen Concentration Risk
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Transdermal versus oral hormone replacement therapy and bone mass density in Turner syndrome patients: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
The diameter of malformation capillaries does not influence the efficacy of photodynamic therapy for facial port-wine stains: a pilot study.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Omega Pharma Ltd

Commercial impact

medium

The recall could lead to a decline in sales and market share for Napralief, allowing competitors to gain traction in the OTC pain management sector.

Regulatory impact

medium

The recall may prompt scrutiny from regulatory bodies regarding compliance and labeling standards, which could affect future approvals or product launches.

What to watch

Monitor for updates on the recall process and any potential regulatory actions or consumer reactions.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.